Nonniekaye Shelburne, CRNP, MS, AOCN

Biography

Nonniekaye Shelburne, CRNP, MS, AOCN, is a program director in the Epidemiology and Genomics Research Program's (EGRP) Clinical and Translational Epidemiology Branch (CTEB). Her research portfolio focuses on improving outcomes for cancer survivors through risk identification and mitigation and management strategies for early and late-onset adverse events related to cancer and cancer treatment.

Ms. Shelburne oversees multiple Programmatic research initiatives across cancer survivorship, with special focus on:

• Early and Late-onset Cancer Treatment-related Adverse Events (e.g., Cardiotoxicity)
• Oncologic Emergencies and the Comprehensive Oncologic Emergencies Research Network (CONCERN)
• Blood and Marrow Transplantation Late Effects
• Prevention and Early Detection of Inherited Cancer Syndromes
• Pediatric, Adolescent and Young Adult Cancer Survivorship

Before joining EGRP in 2010, Ms. Shelburne worked as an acute care nurse practitioner and oncology clinical nurse specialist with the Hematology/Oncology/Stem Cell Transplant Program of Care at the NIH Clinical Center. Her focus was on improving the clinical and research outcomes of patients in phase I and II clinical trials for cancer and hematological disorders. Ms. Shelburne was an associate investigator on cancer patient and caregiver stress, problem solving interventions, and quality of life trials from 2003-2018. Ms. Shelburne’s other interests included development of risk predication tools for patient falls and acute delirium.

Select Publications

Shelburne N, Simonds NI, Jensen RE, Brown J. Cancer-related emergency and urgent care: expanding the research agenda. Emerg Cancer Care. 2022;1(1):4.

Adhikari BB, Shi S, Dimond EP, Shelburne N, Desvigne-Nickens P, Minasian L. Spectrum of National Institutes of Health-funded research in cardio-oncology: a basic, clinical, and observational science perspective. Heart Fail Clin. 2022;18(3):515-528.

Williams CP, Senft Everson N, Shelburne N, Norton WE. Demographic and health behavior factors associated with clinical trial invitation and participation in the United States. JAMA Netw Open. 2021;4(9):e2127792.

Shelburne N, Simonds NI, Adhikari B, et al. Changing hearts and minds: improving outcomes in cancer treatment-related cardiotoxicity. Curr Oncol Rep. 2019;21(1):9.

Rivera D, Gallicchio L, Brown J, Liu B, Kyriacou JN, Shelburne N. Trends in adult cancer-related emergency department utilization: An analysis of data from the Nationwide Emergency Department Sample. JAMA Oncol. 2017;3(10):e172450.

Shaw BE, Hahn T, Martin PJ, et al. National Institutes of Health Hematopoietic Cell Transplantation Late Effects Initiative: Research Methodology and Study Design Working Group report. 2017;23(1);10-23.

Brown J, Grudzen C, Kyriacou J, et al. The emergency care of patients with cancer: setting the research agenda. Ann Emerg Med. 2016 Dec;68(6):706-711.

Shelburne N, Adhikari B, Brell J, et al. Cancer treatment-related cardiotoxicity: current state of knowledge and research priorities. J Natl Cancer Inst. 2014;106(9).

Battiwalla M, Hashmi S, Majhail N, Pavletic S, Savani BN, Shelburne N. National Institutes of Health Hematopoietic Cell Transplantation Late Effects Initiative: developing recommendations to improve survivorship and long-term outcomes. Biol Blood Marrow Transplant. 2017;23(1):6-9.